calicheamicin


Also found in: Wikipedia.

calicheamicin

Any of a family of antitumour antibiotics derived from Micromonospora calichensis and Actinomadura verrucosospora, which have 4000-fold greater antitumoural activity than adriamycin, share a motif of double-triple-double carbon bonds (a so-called enediyene) and cleave DNA in a double-stranded fashion at specific DNA sequences.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase 1 study of an anti-CD33 calicheamicin immunoconjugate.
It binds to CD22 on malignant B-cells and is then taken into the cell, where the cytotoxic agent calicheamicin is released to destroy it.
MYLOTARG is an antibody-drug conjugate (ADC) composed of the cytotoxic agent calicheamicin, attached to a monoclonal antibody (mAB) targeting CD33, an antigen expressed on the surface of myeloblasts in up to 90 percent of AML patients.
Additionally, the mAb's long circulating half-life and low immunogenicity make it the ideal delivery system for powerful cytotoxic compounds such as monomethyl auristatin E (MMAE) and calicheamicin.
This monoclonal antibody is linked to calicheamicin, which is a cytotoxic antibiotic attached to the antibody through a covalent linkage.
According to the study, calicheamicin, a secondary metabolite of Micromonospora echinospora, is what gave the river its toxic reputation.
Mylotarg, a combination of gemtuzumab (IgG4k) conjugated with the cytotoxic antitumor antibiotic calicheamicin, is indicated for the treatment of patients with CD33-positive acute myeloid leukemia in first relapse who are 60 years of age or older.
Whitwam (Mississippi University for Women) who presented work he performed at the Sloan-Kettering Cancer Center on "Cloning and Characterizing the Calicheamicin Self-resi stance gene in Micromonospora echinospora." The second was Alexander Grant Clark, (St.
Mylotarg is an antibody-drug conjugate composed of the cytotoxic agent calicheamicin, attached to a monoclonal antibody targeting CD33, an antigen expressed on the surface of myeloblasts in up to 90 % of AML patients.
The product is an antibody-drug conjugate that includes cytotoxic agent calicheamicin. It is attached to a monoclonal antibody (mAB) targeting CD33.
CLONING AND CHARACTERIZING THE CALICHEAMICIN SELF-RESISTANCE GENE IN MICROMONOSPORA ECHINOSPORA